Posted by Michael Wonder on 28 Mar 2018
In battle to cut drug prices, outcome-based pricing carries big risks for biopharma
28 March 2018 - In a provocative piece entitled “Trump’s Health Secretary Wants To Transform Healthcare. Can He?”, fellow Forbes contributor, Avik Roy, challenges the view that health secretary, Alex Azar, can truly achieve the “value-based transformation of American health care".
Roy carefully goes through the multiple challenges that Azar faces in trying to achieve this, including the “fee for service system”, pricing transparency, and access to patients’ medical data.
He also addresses the topic of cutting drug prices, by questioning the viability of doing this via outcome-based pricing.
